Ipsen

News

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Ipsen appoints Michelle Werner as North America head

Ipsen has appointed biopharma industry veteran Michelle Werner, who recently stepped down as CEO of Alltrna, to lead its North America division.

News

Safety concerns prompt Ipsen to pull Tazverik from market

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen appoints Michelle Werner as North America head

Safety concerns prompt Ipsen to pull Tazverik from market

Servier snaps up cancer biotech Day One in $2.5bn deal

Sobi adds rare lymphoma drug with $580m Innate tie-up

Discover a new era of healthcare panel engagement: Grounded ...

Ipsen

Editor's Picks